Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Breast Cancer
Interventions: DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Doxorubicin|DRUG: Cyclophosphamide|DRUG: Pembrolizumab
Sponsor: University of Kansas Medical Center